In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Nathan M KrahDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0009-0003-8297-7359 Elena Gonzalez-AlvaradoDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USA.ORCID 0009-0006-5574-5861 Amog P UrsDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-7818-2460 Chinmayee GodaDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-3718-585X Yaphet BustosDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0009-0005-6865-5569 James MarvinHealth Science Center Flow Cytometry Core Facility, University of Utah, Salt Lake City, UT, USA.
Bradley D WeaverDepartment of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0009-0007-4009-9163 Spencer GygiDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.
Ashish ToshniwalDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.ORCID 0000-0001-8957-7970 Dennis TowneDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Alvaro Jesus Narbona-PerezDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.
Katarina HeydenDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.ORCID 0000-0002-4731-6825 Juan A Cantres-VelezDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.ORCID 0000-0002-2069-4690 Corey N CunninghamDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.ORCID 0000-0002-1755-4881 Sankalp AroraDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-8162-4119 Ramiro GarzonDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jared RutterDepartment of Biochemistry, University of Utah Medical School, Salt Lake City, UT 84112 USA.ORCID 0000-0002-2710-9765 Adrienne M DorranceDivision of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0002-3685-0053 Amandine ChaixDepartment of Nutrition and Integrative Physiology, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-7007-197X Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KATHARINE S ULLMAN · 1986 to 2026
$72.6MWU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI FUMIHIKO URANO · 2013 to 2026
$27.1MDietary lipids as drivers and therapeutic targets in obesity-accelerated breast cancerUH2CA286584 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI CHAIX, AMANDINE H., DUCKER, GREGORY S · 2024 to 2025
$396kThe impact of pyruvate metabolic fate in myofibroblast differentiation in myelofibrosis.F32HL177926 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Nathan Michael Krah · 2025 to 2026
$164kNCI NIH HHS P30 CA042014NCI NIH HHS UH2 CA286584NHLBI NIH HHS F32 HL177926NIDDK NIH HHS P30 DK020579
6 · The paper itselfAbstract
Obesity expands myeloid progenitors, myelopoiesis and increases the production of monocytes. While weight loss (WL) alleviates aspects of this inflammatory dysregulation, it is not known whether GLP-1 receptor agonists or other traditional modalities of WL differentially modify hematopoietic stem/progenitor cells (HSPCs), hematopoiesis, or inflammatory cell production. To test this, we compared the hematopoietic compartment in lean, obese and weight-reduced mice from tirzepatide treatment and caloric restriction (CR) implemented to match the body weight in both groups. At equal WL, we found CR induced multilineage cytopenias, whereas tirzepatide preserved blood lineages while specifically reducing classical Ly6C
Identifiers
PMID42922752
PMCPMC13684682
What OpenQuestion holds
Textmetadata
Read underepoch 390